Clinical Trial Update: Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer [Phase 1]

View source ↗

Summary

The trial update indicates termination of the Phase 1b/2 study of futibatinib in combination with binimetinib for advanced KRAS-mutant cancer, including non-sma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Binimetinib (binimetinib)
• Futibatinib (futibatinib)

Snippet

Sponsor: Taiho Oncology, Inc. | Conditions: Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations, Non-Small Cell Lung Cancer | Phase 1 | Status: TERMINATED